Latest news
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 15:16:34 GMTDouble shot of Vistagen’s anxiety nasal spray misses in ph. 2 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 14:32:35 GMTTarsus pays $450M for Alkeus and its ph. 3 retinal disease drug - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 14:30:00 GMTBioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 13:40:09 GMTBraveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 12:27:37 GMTActimed gets back rights to wasting disease drug, ending $126M deal with Faraday - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 12:20:19 GMT‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 10:30:00 GMTContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 09:55:15 GMT